Menu
Search
|

Menu

Close
X

Riot Blockchain Inc RIOT.OQ (NASDAQ Stock Exchange Capital Market)

10.24 USD
+0.26 (+2.61%)
As of 1:59 AM IST
chart
Previous Close 9.98
Open 9.85
Volume 238,582
3m Avg Volume 1,116,970
Today’s High 10.43
Today’s Low 9.82
52 Week High 46.20
52 Week Low 3.06
Shares Outstanding (mil) 5.40
Market Capitalization (mil) 39.99
Forward P/E --
Dividend (Yield %) 1.00 ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.415
FY16
-1.006
FY15
-2.261
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
4,249.63
5.77
Price to Book (MRQ)
vs sector
3.62
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-41.57
14.43
Return on Equity (TTM)
vs sector
-44.89
16.13

EXECUTIVE LEADERSHIP

Michael Beeghley
, Since
Salary: --
Bonus: --
John O'Rourke
Chairman of the Board, Chief Executive Officer, Since 2018
Salary: --
Bonus: --
Jeffrey McGonegal
Chief Financial Officer, Corporate Secretary, Since 2010
Salary: $272,005.00
Bonus: $136,003.00
Christopher Ensey
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Edward Lee
Director of Business Development, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

202 6th St Ste 401
CASTLE ROCK   CO   80104-1724

Phone: +1303.7942000

Riot Blockchain Inc., formerly Bioptix, Inc., intends to gain exposure to the block chain ecosystem through targeted investments in the sector, with a primary focus on the bitcoin and Ethereum blockchains. The Company also provides Enhanced Surface Plasmon Resonance (SPR) platform for the detection of molecular interactions. The Company's line of Enhanced SPR instruments are designed to increase the flexibility and reliability of SPR. Its SPR biosensors shed light on important binding parameters that are crucial for determining whether a biologic or small molecule drug efficacious in humans and at what dose a drug should be administered. Its technology is an ultra-sensitive detection platform. The design of its SPR spectrometers allows discrete areas within the sample cell to be interrogated simultaneously. Its biosensors provide information on kinetic processes, binding affinities, analyte concentrations and real-time molecule detection.

SPONSORED STORIES